BMRN
HOLD / NEUTRALMeanRevComposite
54.20
Technical
89.30
Fundamental
42.50
Rank
—
Price
69.55
Hurst
0.19
As of
Aug 12, 2026
Daily
BioMarin Pharmaceutical Inc.
HealthcareBiotechnologyBioMarin Pharmaceutical develops and sells medications to treat rare genetic and metabolic disorders worldwide. The company's marketed therapies address conditions including mucopolysaccharidosis variants, achondroplasia, phenylketonuria, and Batten disease, with a pipeline that includes experimental treatments for growth disorders and muscular dystrophy. The biotechnology firm distributes its products through specialty pharmacies, hospitals, and wholesalers globally.
Market cap
$12.6B
P/E (trailing)
175.68
P/E (forward)
9.82
PEG ratio
0.38
Dividend yield
—
Beta
0.24
52w range
49.26 – 70.98
Return on equity
+1.18%
Profit margin
+2.14%
Revenue growth
+19.90%
Earnings growth
-81.30%
Price history
1Y: 65.00 (+17.9%) · range 49.67–70.24
Cycle position
54/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 16 · NOT READY · exit proximity 0
Conviction
20/ 100 · maturity 100%
VScore.406
Buildup.2034
EMA entry setup.2516
Fundamentals.1543
Volume profile
POC
54.26
Price vs POC
+19.8%
Overhead supply
20%
Runway
open sky
Value area 51.87–62.29 · 20% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.031 | Sep 4, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -6.73% | -1.30% | mature |
| 40d | -6.49% | -1.30% | 21/40d |